Pulse Biosciences (NASDAQ:PLSE) Raised to “Strong-Buy” at Freedom Capmkts

Pulse Biosciences (NASDAQ:PLSE) was upgraded by research analysts at Freedom Capmkts to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks reports.

A number of other research firms have also issued reports on PLSE. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Canaccord Genuity Group upped their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a report on Monday, August 10th. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Finally, Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Stock Up 2.8%

NASDAQ:PLSE opened at $54.43 on Wednesday. The company has a fifty day simple moving average of $39.87 and a two-hundred day simple moving average of $28.84. The company has a market cap of $3.77 billion, a price-to-earnings ratio of -46.13 and a beta of 1.63. Pulse Biosciences has a 52 week low of $12.56 and a 52 week high of $58.90.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. On average, analysts expect that Pulse Biosciences will post -1.29 EPS for the current year.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,001 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were acquired at an average price of $49.95 per share, with a total value of $49,999.95. Following the transaction, the chief operating officer owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders bought 4,095 shares of company stock worth $199,931. 74.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Pulse Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Osterweis Capital Management Inc. purchased a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its holdings in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after buying an additional 1,372 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new stake in Pulse Biosciences during the 2nd quarter worth $241,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.